Pharmaceutical company Orion raises its guidance regarding turnover and profit for the current year.
The company now estimates its turnover to be 1,470–1,510 million euros this year (previously 1,440–1,480 million) and its operating profit to be 370–400 million euros (previously 350–380 million).
According to Orion, the outlook estimates include one milestone payment related to the sale of Nubeqa, from which the company expects to record 70 million euros in the third quarter of the year.
“Orion’s product sales and royalty income have continued to grow faster than expected in the second half of 2024, and this good development is expected to continue during the rest of the year,” the company’s press release says.